4.0 Article

Has there been progress in the treatment of older patients with acute myeloid leukemia?

期刊

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2010.09.012

关键词

acute myeloid leukemia; AML; older; elderly; intensive; age; performance status; karyotype; molecular; gemtuzumab ozogamicin; azacitidine; decitabine; clofarabine; transplantation

资金

  1. Genzyme

向作者/读者索取更多资源

The treatment of older patients with acute myeloid leukemia (AML) has become increasingly important as the population ages. Progress, measured by overall survival rates, has improved in younger patients, perhaps due to the use of intensive post-remission therapies, but it is unclear what will enable progress for older AML patients. The older AML patient population is very heterogeneous, and both patient-specific and leukemia-specific factors must be taken into consideration when choosing the therapy that will most benefit each patient. In addition to standard and intensive chemotherapy regimens, a number of alternative therapies for previously untreated older AML patients are currently being investigated. These include gemtuzumab ozogamicin, azacitidine, decitabine, and clofarabine. (C) 2010 Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据